Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.

ABSTRACT:

Background

Although guidelines for prophylactic human papillomavirus (HPV) vaccination recommend two doses for girls ages 9-14 years, several studies have demonstrated similar protection with one dose. Our objective was to evaluate the long-term health and economic impacts of routine one-dose HPV vaccination compared to (1) no vaccination and (2) two-dose HPV vaccination in a low-income country.

Methods

We used a three-tiered hybrid modeling approach that captured HPV transmission, cervical carcinogenesis, and population demographics to project long-term health and economic outcomes associated with one-dose HPV vaccination (assuming 80% efficacy against HPV-16/18 infections under three waning scenarios) and two-dose HPV vaccination (assuming 100% efficacy over the lifetime)

SUBMITTER: Burger EA 

PROVIDER: S-EPMC6066173 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature